Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 4Withdrawn 3Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Completed × Quality of Life × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡